Playback speed
10 seconds
FDA Approval of Dacomitinib for NSCLC - Is it the Gamechanger in the First-line Treatment?
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
839 views
October 29, 2018
Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR ...
read more ↘ mutation-positive NSCLC, asks whether the demonstrated survival benefit is enough to make dacomitinib a player as first-line treatment.
↖ read less
read more ↘ mutation-positive NSCLC, asks whether the demonstrated survival benefit is enough to make dacomitinib a player as first-line treatment.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung